Section 80
Chapter 79,033

The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2

Jin, Z.; Wang, H.; Duan, Y.; Yang, H.

Biochemical and Biophysical Research Communications 538: 63-71


PMID: 33288200
DOI: 10.1016/j.bbrc.2020.10.091
Accession: 079032762

Download citation:  

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented global health crisis. It is particularly urgent to develop clinically effective therapies to contain the pandemic. The main protease (Mpro) and the RNA-dependent RNA polymerase (RdRP), which are responsible for the viral polyprotein proteolytic process and viral genome replication and transcription, respectively, are two attractive drug targets for SARS-CoV-2. This review summarizes up-to-date progress in the structural and pharmacological aspects of those two key targets above. Different classes of inhibitors individually targeting Mpro and RdRP are discussed, which could promote drug development to treat SARS-CoV-2 infection.

PDF emailed within 0-6 h: $19.90